OOIR: Observatory of International Research

Papers

(The TQCC of Liver International is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Issue Information	255
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Findings	113
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	106
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	104
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	101
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	91
Reply: Herbal‐Induced Liver Injury Identification and Prevention	86
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	80
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	78
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	77
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	77
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	70
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	67
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	65
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	62
Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Ex	62
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	62
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	61
Benefits of Using cT1 for Risk Stratification in MASLD	60
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	58
Reply to “Probiotics for Hepatic Encephalopathy Prevention After TIPS : Still an Open Question”	58
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	55
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	53
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	53
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	53

Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	53
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	49
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years	48
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	46
HBV cure—The light at the end of the tunnel?	45
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	45
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	44
Inside Front Cover	42
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	41
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	41
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	41
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	38
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	38
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	38
Issue Cover	38
Think twice about IgG4‐related diseases before operating on hepatic masses	37
Bringing evidence to the MAFLD‐MASLD debate	37
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	37
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	36
Clarifying Treatment Pathway Differences and Exposure Bias in the CHIEF Cohort Study	36
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection	36
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	35
Integrating PNPLA3 into clinical risk prediction	35
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	34
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	34
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	34
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	34
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	34
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels	34
RETRACTION : Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Inte	33
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	33
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis	32
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	32
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	32
Letter to the editor regarding “Exploring the landscape of steatotic liver disease in the general US population”	32
Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto‐Sinusoidal Vascular Disorder	32
Gender differences of authors of major Hepatology society guidelines during the past 15 years	32
Issue Information	31
¹⁶⁶Ho‐RadioEmbolizaTiOn Using personalized prediCtive dosimetry in patients with Hepatocellular carcinoma: A prospective, single‐centre study (RETOUCH)	31
	31
Enhancing the Understanding of Obesity and Liver Health: Addressing Lifestyle, Socio‐economic and Ethnic Disparities	31
Case‐based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management	31
Bulevirtide for patients with compensated chronic hepatitis delta: A review	31
Response to letter from Skouloudi et al	31
Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis	30
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis	30
Response to: Impact of GLP‐1RA on Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	29
Hepatic cell junctions: Pulling a double‐duty	29
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	28
HLA matching between donors and recipients improves clinical liver transplant graft survival	28

HERACLIS_BLV_D: Increasing Response Rates During 2‐Year Bulevirtide Real‐Life Therapy in Chronic Hepatitis D	28
Health‐related quality of life in patients with primary sclerosing cholangitis: A longitudinal population‐based cohort study	28
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients	27
Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome	27
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures	27
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study	27
Appraisal of AI‐Based Fibrosis Quantification in MASH	27
Axon guidance molecules in liver pathology: Journeys on a damaged passport	26
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use	26
Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis	26
Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets	26
Multiple arterial‐phase MRI with gadoxetic acid improves diagnosis of hepatocellular carcinoma ≤3.0 cm	26
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice	25
Unravelling the Complex Role of Glycine‐Conjugated Bile Acids and Gut‐Liver Axis in Progressive Alcohol‐Related Liver Disease	25
Myeloid Glutamine Synthetase Protects Against Acute Liver Injury in Mice Independent of Its Enzyme Activity	25
NSBBs, EBL or Combined Therapy for High‐Risk Varices: Systematic Review and Meta‐Analysis	25
Red meat intake, faecal microbiome, serum trimethylamine N‐oxide and hepatic steatosis among Chinese adults	25
Autoimmune hepatitis (AIH) following coronavirus (COVID‐19) vaccine—No longer exclusive to mRNA vaccine?	24
Role of Gut‐Derived Endotoxins in Porto‐Sinusoidal Vascular Disorder: Comparison Between patients with and without portal hypertension	24
An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution	24
Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF‐κB Pathway	24
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis	24
Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022	24
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024	24
Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure	23
Adding 100 Hz Spleen Stiffness Measurement to the Baveno VII Model Improves Decompensation Risk Pr	23
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	23
Is it time to get rid of the biopsy mandate in adults with suspected autoimmune hepatitis? Lessons from the COVID‐19 pandemic	22
Author's reply: Plasma corticosteroid‐binding globulin levels in cirrhosis	22
Enhanced muscle function in cause‐specific mortality among patients with NAFLD‐related sarcopenia	22
Third dose of mRNA COVID‐19 vaccine and response: Correspondence	22
3‐Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?	22
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes	22
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	22
Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure	21
Extrahepatic autoimmune diseases do not increase the mortality of autoimmune hepatitis	21
Practice patterns and outcomes associated with intravenous albumin in patients with cirrhosis and acute kidney injury	21
Issue Information	21
Predictors of mid‐term survival after liver transplantation in patients with NAFLD cirrhosis	21
NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database	21
Issue Information	21
Trends in prevalence of probable fibrotic non‐alcoholic steatohepatitis in the United States, 1999–2016	21
Issue Information	21
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?	21
Impairment of Regenerative and Metabolic Pathways in Intestinal Organoids From Patients With MASLD‐Cirrhosis	20
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey	20
Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage peroxisome proliferator‐activated receptor gamma to prevent non‐alcoholic steatohepatitis progression in mice	20
Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)	20
On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients	20
Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways	20
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series	20
Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory	20
Response to Letter to the Editor: “Advancing TMPRSS6‐Targeted Therapy for MASLD: Mechanistic and Translational Perspectives”	20
Bcl‐x_L as prognostic marker and potential therapeutic target in cholangiocarcinoma	20
Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years	20
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study	20
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort	20
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021	19
Apolipoprotein A‐1 protected hepatic ischaemia–reperfusion injury through suppressing macrophage pyroptosis via TLR4–NF‐κB pathway	19
Alcohol‐related liver disease phenotype impacts survival after an acute variceal bleeding episode	19
An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference	19
Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta‐analysis	19
The changing epidemiology of liver diseases in Asia	19
Featured Cover	19
Digital Histopathology and AI: A New Era of Liver Fibrosis Quantification	19
Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno	19
Response to Letter to the Editor: ‘Nanoplastics and MASLD : Unveiling Interorgan Crosstalk and Environmental Modulators’	19
Treatment and the prognosis of hepatocellular carcinoma in Asia	19
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	18
Issue Information	18
Reply to the letter “Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B”	18
Bacterial Infections in Severe Alcohol‐Associated Hepatitis: Methodological Considerations	18
French guidelines on TIPS: Indications and modalities	18
Practical recommendations for biochemical and genetic diagnosis of the porphyrias	18
Issue Information	18
Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial	18
Refining the Safety Perspective of Bulevirtide in Chronic Hepatitis Delta Management	18
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	18
Issue Information	18
Altered ethanol metabolism and increased oxidative stress enhance alcohol‐associated liver injury in farnesoid X receptor‐deficient mice	18

Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis	18
Identification of Distinguishing Features of Drug‐Induced Liver Injury and Liver Injury Associated With Sepsis	18
Follow‐up post‐HCV virological response to DAA in advanced chronic liver disease	18
Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis	17
Risk factors for bleeding hepatocellular adenoma in a United States cohort	17
The utility of hierarchical genetic testing in paediatric liver disease	17
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes	17
Response Letter to: Expanding Perspectives on FIB‐4 as a Predictor of Hepatic and Extrahepatic Malignancy Risk	17
Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent	17
Ketogenic Diet and Hepatic Ischaemia–Reperfusion Injury: Aggravation or Mitigation?	17
Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg‐positive donors to HBsAg‐negative recipients	17
Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease	17
MASLD and MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint	17
Impact of GLP‐1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	17
Pilot hepatitis C micro‐elimination strategy in Pakistani migrants in Catalonia through a community intervention	17
Future anti‐HDV treatment strategies, including those aimed at HBV functional cure	17
FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma	17
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook	17
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	16
Fifteen Years of PNPLA3 : Transforming Hepatology Through Human Genetics	16
Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐N	16
Escherichia coli‐derived outer‐membrane vesicles induce immune activation and progression of cirrhosis in mice and humans	16
	16
Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study	16
Response to Letter to ‘Serum CRP in Durvalumab–Tremelimumab‐Treated HCC : Expanding the Inflammato	16
Response to Letter to ‘Serum CRP in Durvalumab‐Tremelimumab‐Treated HCC : Expanding the Inflammato	16
Issue Information	16
Hepatocellular carcinoma: The virus or the liver?	16
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis	16
Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis	16
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension	16
Issue Information	15
	15
Novel insights into metabolic‐associated steatotic liver disease preclinical models	15
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM	15
MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint?	15
Issue Information	15
Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma: An ELTR Study — Author Reply	15
Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study	15
Histological characterization of liver involvement in systemic mastocytosis	15
Deficient chaperone‐mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85	15
Trajectories of glycaemic traits exhibit sex‐specific associations with hepatic iron and fat content: Results from the KORA‐MRI study	15
Front Cover	15
Issue Information	15
Impact of sarcopenia on postoperative outcomes after hepatectomy in older patients with intrahepatic cholangiocarcinoma: A multicentre cohort study	15
Inhibition of IRE‐1α Alleviates Pyroptosis and Metabolic Dysfunction‐Associated Steatohepatitis by Suppressing Gasdermin D	15
Overcoming the challenges of eliminating viral hepatitis in low‐ and middle‐income countries	15
Sweating it out: How physical activity can combat high genetic risk for nonalcoholic fatty liver disease	14
Autophagy in liver regeneration: Unravelling the endothelial cell's role and therapeutic prospects	14
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma	14
The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma	14
Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China	14
Hepatitis Delta: Ready for primetime?	14
Exosome‐derived miR‐182‐5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway	14
Alpha‐1 Antitrypsin Inclusions Sequester GRP78 in a Bile Acid–Inducible Manner	14
Leflunomide‐induced liver injury: Differences in characteristics and outcomes in Indian and US registries	14
Response Letter to: Zebrafish: An emerging and expedient model for liver studies?	14
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	14
Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis	14
A Transformer‐Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation	14
Spatially segregated defects and IGF1‐responsiveness of hilar and peripheral biliary organoids from a model of Alagille syndrome	14
Inside Front Cover	14
PRO‐C3, liver fibrosis and CKD: The plot thickens	14
Acute alcohol‐associated hepatitis: Latest findings in non‐invasive biomarkers and treatment	14
Optimizing large language models in digestive disease: strategies and challenges to improve clinical outcomes	14
Preoperative magnetic resonance imaging‐based prognostic model for mass‐forming intrahepatic cholangiocarcinoma	14
Zebrafish: An emerging and expedient model for liver studies?	14
Incidence and risk factors of drug‐induced liver injury	14
The Relationship Between Ferroptosis and Metabolic Dysfunction‐Associated Fatty Liver Disease	14
Epidemiology and surveillance of autoimmune hepatitis in Asia	14
Response to: “The Role of Platelets in MASLD: From Mechanisms to Clinical Implications”	14
CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis	14
Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome	14
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	14
Response to: Letter to the Editor “Child‐Turcotte‐Pugh score as a model for organ allocation in liver transplantation, perhaps old is still gold”	14
Stenting of ductus venosus as a palliation for portal hypertension because of neonatal cirrhosis	14
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma	14
PNPLA3 variation and kidney disease	14
Response Letter to: Association of thyroid function with nonalcoholic fatty liver disease in recent‐onset diabetes	14
Nuclear translocation of YAP drives BMI‐associated hepatocarcinogenesis in hepatitis B virus infection	14
Delta virus infection and hepatocellular carcinoma	14
	14
Management of alcoholic hepatitis: A clinical perspective	14
	14
A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study	14
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030	14
Letter regarding ‘mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome’	13
Response: Methodological Considerations for Assessing the Long‐Term Impact of Maternal MASLD on Offspring Health	13
Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community	13
The impact of macro‐ and micro‐steatosis on the outcomes of patients who undergo liver transplant: Analysis of the UNOS‐STAR database	13
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	13
Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US	13
MAIT cells ameliorate liver fibrosis by enhancing the cytotoxicity of NK cells in cholestatic murine models	13
Not So Quiet on the Viral Front: Low‐Level HBV Viraemia Undermines Immunotherapy in HCC	13
Material deprivation is associated with liver stiffness and liver‐related outcomes in people with HIV	13